Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
5.94
+0.20 (3.48%)
At close: Oct 26, 2026, 4:00 PM EDT
6.00
+0.06 (1.02%)
Pre-market: Oct 27, 2026, 4:16 AM EDT
Phathom Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Phathom Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $19.64. The average 1-year stock price forecast is 230.64% higher than the current stock price, while the lowest is $10 (+68.35%) and the highest is $29 (+388.22%).
Price Target: $19.64 (+230.64%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Phathom Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 8 | 8 | 8 | 8 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 11 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Oct 23, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains $20 → $15 | Buy | Maintains | $20 → $15 | +152.53% | Oct 21, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $26 | Buy | Maintains | $26 | +337.71% | Sep 21, 2026 |
| Leerink Partners | Leerink Partners | Hold Initiates $10 | Hold | Initiates | $10 | +68.35% | Sep 9, 2026 |
| Barclays | Barclays | Buy Maintains $14 | Buy | Maintains | $14 | +135.69% | Aug 17, 2026 |
Financial Forecast
Revenue This Year
315.24M
from 175.11M
Increased by 80.03%
Revenue Next Year
489.37M
from 315.24M
Increased by 55.24%
EPS This Year
-0.04
from -2.06
EPS Next Year
0.96
from -0.04
EPS and Forward PE are based on non-GAAP adjusted numbers.